SGLT2: A potential target for the pharmacogenetics of Type 2 diabetes?

Pharmacogenomics

Volumn 14, Issue 7, 2013, Pages 825-833

  Tönjes, Anke ^a,b   Kovacs, Peter ^a,b  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b UNIVERSITY HOSPITAL LEIPZIG   (Germany)

Author keywords

diabetes; glucose; SGLT2; SLC5A2

Indexed keywords

GLUCOSE; SODIUM GLUCOSE COTRANSPORTER 2;

CHROMOSOME 16; DIABETIC PATIENT; DNA POLYMORPHISM; GENE; GENE MAPPING; GENE MUTATION; GENETIC VARIABILITY; GLUCONEOGENESIS; GLUCOSE ABSORPTION; GLUCOSE HOMEOSTASIS; GLUCOSURIA; GLYCEMIC CONTROL; HUMAN; KIDNEY; KIDNEY TUBULE ABSORPTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHARMACOGENETICS; PHARMACOGENOMICS; RENAL DIABETES; REVIEW; SCL5A2 GENE;

DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; PHARMACOGENETICS; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 84877646384     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.13.61     Document Type: Review

References (80)

1. Shields BM, Hicks S, Shepherd MH, Colclough K, Hattersley AT, Ellard S. Maturity-onset diabetes of the young (MODY): how many cases are we missing? Diabetologia 53, 2504-2508 (2010).
2. Gloyn AL. Glucokinase (GCK) mutations in hyper-and hypoglycemia: maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemia of infancy. Hum. Mut. 22, 353-362 (2003).
3. Gloyn AL, Ellard S. Defining the genetic aetiology monogenic diabetes can improve treatment. Expert Opin. Pharmacother. 7, 1759-1767 (2006).
4. Fajans SS, Bell GI, Polonsky KS. Mechanisms of disease: molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young. N. Engl. J. Med. 345, 971-980 (2001).
5. Gloyn AL, Pearson ER, Antcliff JF, et al. Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N. Engl. J. Med. 350, 1838-1849 (2004).
6. Hattersley AT, Ashcroft FM. Activating mutations in Kir6.2 and neonatal diabetes -new clinical syndromes, new scientific insights, and new therapy. Diabetes 54, 2503-2513 (2005).
7. Flanagan SE, Patch AM, Mackay DJG, et al. Mutations in ATP-sensitive K+ channel genes cause transient neonatal diabetes and permanent diabetes in childhood or adulthood. Diabetes 56, 1930-1937 (2007).
8. Pearson ER, Flechtner I, Njolstad PR, et al. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N. Engl. J. Med. 355, 467-477 (2006).
9. Smith RJ, Nathan DM, Arslanian SA, Groop L, Rizza RA, Rotter JI. Individualizing therapies in Type 2 diabetes mellitus based on patient characteristics: what we know and what we need to know. J. Clin. Endocrinol. Metab. 95, 1566-1574 (2010).
10. Altshuler D, Hirschhorn JN, Klannemark M, et al. The common PPAR b Pro12Ala polymorphism is associated with decreased risk of Type 2 diabetes. Nat. Genet. 26, 76-80 (2000).
11. O'Rahilly S, Barroso I, Wareham NJ. Genetic factors in Type 2 diabetes: the end of the beginning? Science 307, 370-373 (2005).
12. Grant SF, Thorleifsson G, Reynisdottir I, et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of Type 2 diabetes. Nat. Genet. 38, 320-323 (2006).
13. Clatworthy JP, Subramanian V. Stem cells and the regulation of proliferation, differentiation and patterning in the intestinal epithelium: emerging insights from gene expression patterns, transgenic and gene ablation studies. Mech. Dev. 101, 3-9 (2001).
14. Cauchi S, Meyre D, Dina C, et al. Transcription factor TCF7L2 genetic study in the French population -expression in human b-cells and adipose tissue and strong association with Type 2 diabetes. Diabetes 55, 2903-2908 (2006).
15. Cauchi S, El Achhab Y, Choquet H, et al. TCF7L2 is reproducibly associated with Type 2 diabetes in various ethnic groups: a global meta-analysis. J. Mol. Med. 85, 777-782 (2007).
16. Damcott CM, Pollin TI, Reinhart LJ, et al. Polymorphisms in the transcription factor 7-like 2 (TCF7L2) gene are associated with Type 2 diabetes in the Amish -replication and evidence for a role in both insulin secretion and insulin resistance. Diabetes 55, 2654-2659 (2006).
17. Florez JC, Jablonski KA, Bayley N, et al. TCF7L2 polymorphisms and progression to diabetes in the diabetes prevention program. N. Engl. J. Med. 355, 241-250 (2006).
18. Grant SFA, Thorleifsson G, Helgason A, et al. Refinement of the association between the TCF7L2 gene and Type 2 diabetes in a west African population. Diabetologia 49, 16-17 (2006).
19. Groves CJ, Zeggini E, Minton J, et al. Association analysis of 6,736 U.K. subjects provides replication and confirms TCF7L2 as a Type 2 diabetes susceptibility gene with a substantial effect on individual risk. Diabetes 55, 2640-2644 (2006).
20. Helgason A, Palsson S, Thorleifsson G, et al. Refining the impact of TCF7L2 gene variants on Type 2 diabetes and adaptive evolution. Nat. Genet. 39, 218-225 (2007).
21. Kimber CH, Doney AS, Pearson ER, et al. TCF7L2 in the Go-DARTS study: evidence for a gene dose effect on both diabetes susceptibility and control of glucose levels. Diabetologia 50, 1186-1191 (2007).
22. Scott LJ, Bonnycastle LL, Willer CJ, et al. Association of transcription factor 7-like 2 (TCF7L2) variants with Type 2 diabetes in a Finnish sample. Diabetes 55, 2649-2653 (2006).
23. Wang J, Kuusisto J, Vanttinen M, et al. Variants of transcription factor 7-like 2 (TCF7L2) gene predict conversion to Type 2 diabetes in the Finnish Diabetes Prevention Study and are associated with impaired glucose regulation and impaired insulin secretion. Diabetologia 50, 1192-1200 (2007).
24. Zeggini E, McCarthy MI. TCF7L2: the biggest story in diabetes genetics since HLA? Diabetologia 50, 1-4 (2007).
25. Zhang C, Qi L, Hunter DJ, et al. Variant of transcription factor 7-like 2 (TCF7L2) gene and the risk of Type 2 diabetes in large cohorts of U.S. women and men. Diabetes 55, 2645-2648 (2006).
26. Pearson ER, Donnelly LA, Kimber C, et al. Variation in TCF7L2 influences therapeutic response to sulfonylureas -a GoDARTs study. Diabetes 56, 2178-2182 (2007).
27. Holstein A, Hahn M, Korner A, Stumvoll M, Kovacs P. TCF7L2 and therapeutic response to sulfonylureas in patients with Type 2 diabetes. BMC Med. Genet. 12, 30 (2011).
28. Zhou K, Bellenguez C, Spencer CC, et al. Common variants near ATM are associated with glycemic response to metformin in Type 2 diabetes. Nat. Genet. 43, 117-120 (2011).
29. van Leeuwen N, Nijpels G, Becker ML, et al. A gene variant near ATM is significantly associated with metformin treatment response in Type 2 diabetes: a replication and meta-analysis of five cohorts. Diabetologia 55, 1971-1977 (2012).
30. Nair S, Wilding JPH. Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus. J. Clin. Endocrinol. Metab. 95, 34-42 (2010).
31. Lee YJ, Lee YJ, Han HJ. Regulatory mechanisms of Na(+)/glucose cotransporters in renal proximal tubule cells. Kidney Int. 72, S27-S35 (2007).
32. Abdul-Ghani MA, Defronzo R A. Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in Type 2 diabetes mellitus. Endocr. Pract. 14, 782-790 (2008).
33. Wright E, Turk E. The sodium/glucose cotransport family SLC5. Pflugers Arch. Eur. J. Physiol. 447, 510-518 (2004).
34. Wright EM. Renal Na+-glucose cotransporters. Am. J. Physiol. Renal Physiol. 280, F10-F18 (2001).
35. Powell DR, DaCosta CM, Gay J, et al. Improved glycemic control in mice lacking Sglt1 and Sglt2. Am. J. Physiol. Endocrinol. Metabol. 304(2), E117-E130 (2012).
36. Kamran M, Peterson RG, Dominguez JH. Overexpression of GLUT2 gene in renal proximal tubules of diabetic Zucker rats. J. Am. Soc. Nephrol. 8, 943-948 (1997).
37. Marks J, Carvou NJC, Debnam ES, Srai SK, Unwin RJ. Diabetes increases facilitative glucose uptake and GLUT2 expression at the rat proximal tubule brush border membrane. J. Physiol. 553, 137-145 (2003).
38. Noonan WT, Shapiro VM, Banks RO. Renal glucose reabsorption during hypertonic glucose infusion in female streptozotocin-induced diabetic rats. Life Sci. 68, 2967-2977 (2001).
39. Freitas HS, Anhe GF, Melo KFS, et al. Na+-glucose transporter-2 messenger ribonucleic acid expression in kidney of diabetic rats correlates with glycemic levels: involvement of hepatocyte nuclear factor-1a expression and activity. Endocrinology 149, 717-724 (2008).
40. Rahmoune H, Thompson PW, Ward JM, Smith CD, Hong G, Brown J. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes 54, 3427-3434 (2005).
41. Pontoglio M, Sreenan S, Roe M, et al. Defective insulin secretion in hepatocyte nuclear factor 1a-deficient mice. J. Clin. Invest. 101, 2215-2222 (1998).
42. Pontoglio M, Prie D, Cheret C, et al. HNF1 a controls renal glucose reabsorption in mouse and man. EMBO Rep. 1, 359-365 (2000).
43. Pontoglio M, Barra J, Hadchouel M, et al. Hepatocyte nuclear factor 1 inactivation results in hepatic dysfunction, phenylketonuria, and renal fanconi syndrome. Cell 84, 575-585 (1996).
44. Menzel R, Kaisaki PJ, Rjasanowski I, Heinke P, Kerner W, Menzel S. A low renal threshold for glucose in diabetic patients with a mutation in the hepatocyte nuclear factor-1a (HNF-1a) gene. Diab. Med. 15, 816-820 (1998).
45. Schiffer M, Susztak K, Ranalletta M, Raff AC, Böttinger EP, Charron MJ. Localization of the GLUT8 glucose transporter in murine kidney and regulation in vivo in nondiabetic and diabetic conditions. Am. J. Physiol. Renal Physiol. 289, F186-F193 (2005).
46. Doege H, Schürmann A, Bahrenberg G, Brauers A, Joost HG. GLUT8, a novel member of the sugar transport facilitator family with glucose transport activity. J. Biol. Chem. 275, 16275-16280 (2000).
47. Gorboulev V, Schürmann A, Vallon V, et al. Na+-d-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion. Diabetes 61, 187-196 (2012).
48. Calado J, Loeffler J, Sakallioglu O, et al. Familial renal glucosuria: SLC5A2 mutation analysis and evidence of salt-wasting. Kidney Int. 69, 852-855 (2006).
49. Calado J, Sznajer Y, Metzger D, et al. Twenty-one additional cases of familial renal glucosuria: absence of genetic heterogeneity, high prevalence of private mutations and further evidence of volume depletion. Nephrol. Dial. Transplant. 23, 3874-3879 (2008).
50. Santer R, Kinner M, Lassen CL, et al. Molecular analysis of the SGLT2 gene in patients with renal glucosuria. J. Am. Soc. Nephrol. 14, 2873-2882 (2003).
51. Yu L, Lv JC, Zhou XJ, Zhu L, Hou P, Zhang H. Abnormal expression and dysfunction of novel SGLT2 mutations identified in familial renal glucosuria patients. Hum. Genet. 129, 335-344 (2011).
52. Santer R, Calado J. Familial renal glucosuria and SGLT2: from a Mendelian trait to a therapeutic target. Clin. J. Am. Soc. Nephrol. 5, 133-141 (2010).
53. Katsuno K, Fujimori Y, Takemura Y, et al. Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level. J. Pharmacol. Exp. Ther. 320, 323-330 (2007).
54. Fujimori Y, Katsuno K, Ojima K, et al. Sergliflozin etabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats. Eur. J. Pharmacol. 609, 148-154 (2009).
55. MacDonald FR, Peel JE, Jones HB, et al. The novel sodium glucose transporter 2 inhibitor dapagliflozin sustains pancreatic function and preserves islet morphology in obese, diabetic rats. Diabetes Obes. Metab. 12, 1004-1012 (2010).
56. Han S, Hagan DL, Taylor JR, et al. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes 57, 1723-1729 (2008).
57. Jurczak MJ, Lee HY, Birkenfeld AL, et al. SGLT2 deletion improves glucose homeostasis and preserves pancreatic b-cell function. Diabetes 60, 890-898 (2011).
58. Komoroski B, Vachharajani N, Feng Y, Li L, Kornhauser D, Pfister M. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with Type 2 diabetes mellitus. Clin. Pharmacol. Ther. 85, 513-519 (2009).
59. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with Type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 375, 2223-2233 (2010).
60. Wilding JPH, Woo V, Soler NG, et al. Long-term efficacy of dapagliflozin in patients with Type 2 diabetes mellitus receiving high doses of insulin a randomized trial. Ann. Int. Med. 156, 405-415 (2012).
61. Ehrenkranz JRL, Lewis NG, Kahn RC, Roth J. Phlorizin: a review. Diabetes Metab. Res. Rev. 21, 31-38 (2005).
62. Grempler R, Thomas L, Eckhardt M, et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes. Metab. 14, 83-90 (2012).
63. Chen LH, Leung PS. Inhibition of the sodium glucose co-transporter-2: its beneficial action and potential combination therapy for Type 2 diabetes mellitus. Diabetes Obes. Metab. 15(5), 392-402 (2013).
64. Jones D. Diabetes field cautiously upbeat despite possible setback for leading SGLT2 inhibitor. Nat. Rev. Drug Discov. 10, 645-646 (2011).
65. Sheridan C. SGLT2 inhibitors race to enter Type-2 diabetes market. Nat. Biotech. 30, 899-900 (2012).
66. Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozin monotherapy in Type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, Phase 3 trial. Diabetes Care 33, 2217-2224 (2010).
67. Hussey EK, Clark RV, Amin DM, et al. Single-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy volunteers and patients with Type 2 diabetes mellitus. J. Clin. Pharmacol. 50, 623-635 (2010).
68. Wilding JPH, Norwood P, T'joen C, Bastien A, List JF, Fiedorek FT. A study of dapagliflozin in patients with Type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care 32, 1656-1662 (2009).
69. Rosenstock J, Vico M, Wei L, Salsali A, List JF. Effects of dapagliflozin, an SGLT2 inhibitor, on HbA1c, body weight, and hypoglycemia risk in patients with Type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care 35, 1473-1478 (2012).
70. Musso G, Gambino R, Cassader M, Pagano G. A novel approach to control hyperglycemia in Type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials. Ann. Med. 44, 375-393 (2012).
71. Liu J, Lee T, DeFronzo RA. Why do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans? Diabetes 61, 2199-2204 (2012).
72. Ferrannini E, Solini A. SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat. Rev. Endocrinol. 8, 495-502 (2012).
73. Nauck MA, Del Prato S, Meier JJ, et al. Dapagliflozin versus glipizide as add-on therapy in patients with Type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care 34, 2015-2022 (2011).
74. Zanardi TA, Han SC, Jeong EJ, et al. Pharmacodynamics and subchronic toxicity in mice and monkeys of ISIS 388626, a second-generation antisense oligonucleotide that targets human sodium glucose cotransporter 2. J. Pharmacol. Exp. Ther. 343, 489-496 (2012).
75. Zambrowicz B, Freiman J, Brown PM, et al. LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with Type 2 diabetes in a randomized, placebo-controlled trial. Clin. Pharmacol. Ther. 92, 158-169 (2012).
76. Zambrowicz B, Ding ZM, Ogbaa I, et al. Effects of LX4211, a dual SGLT1/SGLT2 inhibitor, plus sitagliptin on postprandial active GLP-1 and glycemic control in Type 2 diabetes. Clin. Ther. 35(3), 273-285.e7 (2013).
77. List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium-glucose cotransport inhibition with dapagliflozin in Type 2 diabetes. Diabetes Care 32, 650-657 (2009).
78. Zhang L, Feng Y, List J, Kasichayanula S, Pfister M. Dapagliflozin treatment in patients with different stages of Type 2 diabetes mellitus: effects on glycaemic control and body weight. Diabetes Obes. Metab. 12, 510-516 (2010).
79. Enigk U, Breitfeld J, Schleinitz D, et al. Role of genetic variation in the human sodium-glucose cotransporter 2 gene (SGLT2) in glucose homeostasis. Pharmacogenomics 12, 1119-1126 (2011).
80. Wheeler E, Barroso I. Genome-wide association studies and Type 2 diabetes. Brief Funct. Genomics 10, 52-60 (2011).